Achieve Life Sciences will present Phase 3 study data on cytisinicline's efficacy in nicotine craving reduction at the ATS Conference. Achieve Life Sciences, Inc. has announced that additional ...
BOSTON, Nov. 3, 2025 /PRNewswire/ -- Servier today announced longer-term data from the Phase 3 INDIGO trial evaluating VORANIGO® (vorasidenib) versus placebo in patients with Grade 2 mutant isocitrate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback